Whitehawk Therapeutics: 'Hold' On Name Change And Next Generation PTK7 ADC Targeting

Whitehawk Therapeutics pivots to focus on three next-generation antibody-drug conjugates [ADCs] after selling FYARRO and rebranding from Aadi Bioscience. I downgrade WHWK from 'Strong Buy' to 'Hold' due to the early-stage pipeline, competitive landscape, and unproven efficacy/safety of modified ADCs. Key catalysts include phase 1 data readouts for HWK-007 and HWK-016 in 1H 2027 and an IND filing for HWK-206 in mid-2026.